MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer

Cytogenetic and Genome Research

Volumn 146, Issue 1, 2015, Pages 1-8

  Zhen, Qiang ^a   Liu, Junfeng ^a   Gao, Lina ^b   Liu, Jiabao ^c   Wang, Renfeng ^c   Chu, Weiwei ^c   Zhang, Yaxiao ^c   Tan, Guoliang ^c   Zhao, Xiaojian ^c   Lv, Baolei ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

^c Shijiazhuang No1 Hospital   (China)

Author keywords

c Met; EGFR; miR 200a; Non small cell lung cancer; TKI resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MESSENGER RNA; MICRORNA 200A; SCATTER FACTOR RECEPTOR; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN; QUINAZOLINE DERIVATIVE;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; BINDING SITE; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE;

EID: 84941935987     PISSN: 14248581     EISSN: 1424859X     Source Type: Journal    
DOI: 10.1159/000434741     Document Type: Article

References (32)

1. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, et al: Mir-200 expression regulates epithelialto-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15: 5060-5072 (2009).
2. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297 (2004).
3. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233 (2009).
4. Bredin CG, Liu Z, Klominek J: Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines. Anticancer Res 23: 4877-4884 (2003).
5. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, et al: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116: 2695-2706 (2006).
6. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043 (2007).
7. Gao Y, Fan X, Li W, Ping W, Deng Y, Fu X: miR-138-5p reverses gefitinib resistance in nonsmall cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun 446: 179-186 (2014).
8. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, et al: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692-697 (2008).
9. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, et al: Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104: 12867-12872 (2007).
10. Janne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in nonsmall-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23: 3227-3234 (2005).
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90 (2011).
12. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC: Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806-8811 (2000).
13. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792 (2005).
14. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158 (2003).
15. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, et al: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670 (2005).
16. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838 (2005).
17. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139 (2004).
18. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500 (2004).
19. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568 (2005).
20. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73 (2005).
21. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, et al: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261-271 (1994).
22. Qiao H, Hung W, Tremblay E, Wojcik J, Gui J, et al: Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86: 665-677 (2002).
23. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30 (2013).
24. Sipeki S, Bander E, Buday L, Farkas G, Bacsy E, et al: Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 map kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal 11: 885-890 (1999).
25. Soria JC, Mok TS, Cappuzzo F, Janne PA: EGFRmutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 38: 416-430 (2012).
26. Stamos J, Sliwkowski MX, Eigenbrot C: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272 (2002).
27. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (iressa survival evaluation in lung cancer). Lancet 366: 1527-1537 (2005).
28. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA: Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line h3255. Cancer Res 64: 7241-7244 (2004).
29. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261 (2006).
30. Wang F, Chan LW, Law HK, Cho WC, Tang P, et al: Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA: miRNA regression model supported by target prediction databases. Genomics 104: 504-511 (2014).
31. Yamaguchi G, Takanashi M, Tanaka M, Fujita K, Ohira T, et al: Isolation of miRNAs that target EGFR mRNA in human lung cancer. Biochem Biophys Res Commun 420: 411-416 (2012).
32. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227 (2007).